Tonsil-derived mesenchymal stem cells alleviate skin inflammation by modulating neutrophil extracellular trap formation and T cell migration
Fig 3
Effects of T-MSCs in the DNCB-induced skin inflammation model.
(A) Experimental scheme showing the timeline of DNCB application and T-MSC injection in the mouse model of skin inflammation. DNCB or vehicle was applied on days 1, 2, 3, 8, and 9. T-MSCs or PBS were administered intravenously on day 2. Mice were sacrificed on day 10 for analysis. (B) Body weight changes over 10 days following DNCB treatment and T-MSC injection. The graph shows body weight as a percentage of baseline (day 0) for each group (n = 4 per group). (C) Representative photographs of dorsal skin from each group taken at sacrifice on day 10. (D) Macroscopic images of lymph nodes (LN) and spleens (SP) harvested from each group. (E) Quantification of LN length across groups. DNCB treatment significantly increased LN length compared with vehicle (n = 2 per group). (F) Quantification of SP length across groups. Data were analyzed using two-way ANOVA, followed by Tukey’s post hoc test for multiple comparison (* P < 0.05 and ** P < 0.01). Vehicle (V), vehicle + T-MSCs (V + T), DNCB (D), and DNCB + T-MSCs (D + T).